Gaurav Batti

Amgen Europe has launched Aranesp, a second-generation EPO product in a market dominated by Johnson & Johnson's pioneering Eprex (US name Procrit), followed by NeoRecormon from Roche. One year after the launch, the sales and market share of Aranesp are below target.

Published 04 Jan 2007

Reference 5410

Topic Marketing

Industry Pharmaceuticals

Region Europe

View case